Treating primary membranous nephropathy with extremely high titer of anti-phospholipase A2 receptor antibodies: A case of failed treatment with very high-dose rituximab

Rituximab (RTX) is the anti-CD20 monoclonal antibody that has been used as the first-line therapy for primary membranous nephropathy (PMN) in recent years. However, the optimal dosing regimen and timing of RTX, or combination with other immunosuppressants, especially in patients with extremely high...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Clinical nephrology 2024-09
Hauptverfasser:	Sun, Jingshu, Wu, Shengqin, Yin, Fang, Zhang, Kunying, Wang, Jianying
Format:	Artikel
Sprache:	eng
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!